Alzheimer’s

Biotech By Adam Feuerstein

‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment

Biotech By Adam Feuerstein

Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions

In the Lab By Megan Molteni

Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment

Biotech By Adam Feuerstein

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

Pharma By Adam Feuerstein

In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment

Biotech By Damian Garde

What to look for in Lilly’s eagerly awaited Alzheimer’s data

Aducanumab study participant Alzheimer's

Biotech By Damian Garde and Adam Feuerstein

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Biotech By Matthew Herper

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

Biotech By Adam Feuerstein, Damian Garde and Meg Tirrell

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Biotech By Damian Garde and Adam Feuerstein

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Pharmalot By Ed Silverman

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

Biotech By Damian Garde and Adam Feuerstein

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Biotech By Adam Feuerstein and Damian Garde

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

Biotech By Adam Feuerstein

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech By Damian Garde

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

First Opinion By Dennis J. Selkoe

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

In the Lab By Sharon Begley

New prize offers $2 million for finding key to Alzheimer’s in past research

Pharma By Sharon Begley

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalot By Ed Silverman

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

Adam's Take By Adam Feuerstein

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

Alzheimer's brain illustration - Loss of connection between cells

Pharmalot By Ed Silverman

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

Health By Damian Garde

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

Biotech By Sharon Begley

Most Read

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Hospitalized adults need their caregivers — they aren’t visitors

All Coverage

‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment

Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions

Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment

What to look for in Lilly’s eagerly awaited Alzheimer’s data

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Startup Arkuda targets rapidly advancing, rare form of dementia

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

New prize offers $2 million for finding key to Alzheimer’s in past research

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

In small Alzheimer’s study, hints of modest benefit from unusual drug

Subscribe to STAT for $15 per month lorem ipsum